ArticleBriefings in bioinformatics2026
ML-ExonCNV: a robust XGBoost multi-expert ensemble framework for rare exon CNV detection in whole-exome sequencing data.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- X-Linked Intellectual Developmental Disorder-93 Caused by BRWD3 Mutation in Females: A Case Report and Literature Review.Molecular genetics & genomic medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Copy number variants (CNVs) have been shown to play a significant role in the pathogenesis of various human diseases. Although several tools have been developed for detecting CNVs based on whole-exome sequencing (WES) data, their performance remains suboptimal for small exon-level CNVs (exCNVs). This is primarily due to multiple technical variabilities, including probe capture efficiency, mappability, exon size, batch effects, experimental background noise bias, and control sample selection, all of which can lead to false negatives and false positives in exCNV detection. To address these challenges, we developed ML-ExonCNV, which innovatively integrates the XGBoost machine learning model with a multi-expert ensemble approach. The model was trained using 14 features derived from 22 364 real-world, quantitative polymerase chain reaction-validated rare exCNVs. Evaluation on a test set of 492 real WES and the NA12878 gold-standard dataset demonstrated that ML-ExonCNV outperformed widely used tools such as GATK-gCNV, ExomeDepth, and CNVkit. Notably, ML-ExonCNV can detect large segmental CNVs, mosaic CNVs, and breakpoint CNVs on exon region. Furthermore, our analysis revealed recurrent exCNV-associated genes and their phenotypic correlations. Neurodevelopmental and musculoskeletal abnormalities were identified as the most frequently associated phenotypes with high-recurrence exCNVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.